John Harrison

10.2k total citations · 3 hit papers
150 papers, 7.1k citations indexed

About

John Harrison is a scholar working on Psychiatry and Mental health, Physiology and Cognitive Neuroscience. According to data from OpenAlex, John Harrison has authored 150 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Psychiatry and Mental health, 38 papers in Physiology and 33 papers in Cognitive Neuroscience. Recurrent topics in John Harrison's work include Dementia and Cognitive Impairment Research (41 papers), Alzheimer's disease research and treatments (23 papers) and Functional Brain Connectivity Studies (11 papers). John Harrison is often cited by papers focused on Dementia and Cognitive Impairment Research (41 papers), Alzheimer's disease research and treatments (23 papers) and Functional Brain Connectivity Studies (11 papers). John Harrison collaborates with scholars based in United Kingdom, United States and Netherlands. John Harrison's co-authors include J. Schultz, Simon Baron‐Cohen, Craig Ritchie, Christopher Kennard, Henrik Zetterberg, Kaj Blennow, Patrick Bolton, Masud Husain, Lars Lannfelt and Colin L. Masters and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

John Harrison

145 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Studies on the chlorinating activity of myeloperoxidase.

1976 820 citations John Harrison et al. Journal of Biological Chemistry profile →
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

2008 586 citations Lars Lannfelt, Kaj Blennow et al. profile →
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

2020 208 citations Henrik Zetterberg, Kaj Blennow et al. Alzheimer s Research & Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Harrison United Kingdom	44	2.0k	1.5k	1.2k	1.1k	1.0k	150	7.1k
Rolf Adolfsson Sweden	66	3.0k 1.4×	2.0k 1.4×	3.7k 3.1×	1.2k 1.1×	2.1k 2.1×	250	13.9k
Brian E. Leonard Ireland	48	1.0k 0.5×	664 0.5×	1.6k 1.4×	524 0.5×	1.3k 1.3×	147	9.5k
Shigenobu Kanba Japan	64	1.7k 0.8×	2.6k 1.8×	3.4k 2.8×	1.5k 1.3×	1.8k 1.8×	324	14.1k
Manfred Uhr Germany	57	1.2k 0.6×	874 0.6×	1.2k 1.0×	842 0.7×	1.7k 1.7×	199	10.2k
Michael G. Ziegler United States	71	4.2k 2.1×	1.1k 0.8×	1.4k 1.2×	1.2k 1.0×	3.0k 2.9×	407	17.0k
Robert K. McNamara United States	49	1.8k 0.9×	1.1k 0.8×	1.6k 1.3×	432 0.4×	1.6k 1.6×	180	8.6k
Yang An United States	53	3.1k 1.5×	2.1k 1.5×	2.2k 1.9×	854 0.7×	1.8k 1.7×	190	8.8k
Klaus Wiedemann Germany	48	805 0.4×	953 0.7×	759 0.6×	930 0.8×	706 0.7×	288	7.1k
Masatoshi Itoh Japan	40	778 0.4×	1.3k 0.9×	851 0.7×	478 0.4×	529 0.5×	199	5.5k
Richard Dodel Germany	60	2.7k 1.3×	1.3k 0.9×	2.3k 1.9×	351 0.3×	1.7k 1.7×	289	11.9k

Countries citing papers authored by John Harrison

Since Specialization

Citations

This map shows the geographic impact of John Harrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Harrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Harrison more than expected).

Fields of papers citing papers by John Harrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Harrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Harrison. The network helps show where John Harrison may publish in the future.

Co-authorship network of co-authors of John Harrison

This figure shows the co-authorship network connecting the top 25 collaborators of John Harrison. A scholar is included among the top collaborators of John Harrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Harrison. John Harrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rolan, Paul, Jonathan R. Seckl, Jack A. Taylor, et al.. (2025). Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease. Clinical Pharmacology in Drug Development. 14(2). 105–115.

Dasgupta, Indranil, Aghogho Odudu, Jyoti Baharani, et al.. (2024). Evaluation of effect of cooled haemodialysis on cognition in patients with end-stage kidney disease (ECHECKED) feasibility randomised controlled trial results. BMC Nephrology. 25(1). 466–466. 2 indexed citations

Boer, Casper de, Marissa D. Zwan, Roos J. Jutten, et al.. (2024). Digital remote assessment of speech acoustics in cognitively unimpaired adults: feasibility, reliability and associations with amyloid pathology. Alzheimer s Research & Therapy. 16(1). 176–176. 3 indexed citations

Hendriksen, Heleen M.A., John Harrison, Everard G.B. Vijverberg, et al.. (2023). Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups. Neurology. 102(2). e207978–e207978. 18 indexed citations

Gregory, Sarah, Nicklas Linz, Alexandra König, et al.. (2022). Remote data collection speech analysis and prediction of the identification of Alzheimer’s disease biomarkers in people at risk for Alzheimer’s disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol. BMJ Open. 12(3). e052250–e052250. 11 indexed citations

Dalby, Maria, Peter Annas, & John Harrison. (2022). Further validation of the THINC‐it tool and extension of the normative data set in a study ofn = 10.019 typical controls. International Journal of Methods in Psychiatric Research. 31(4). e1922–e1922. 6 indexed citations

Vijverberg, Everard G.B., Asger Reinstrup Bihlet, Kim Henriksen, et al.. (2021). Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD. Alzheimer s Research & Therapy. 13(1). 142–142. 27 indexed citations

Wessels, Alette M., Chris J. Edgar, Pradeep J. Nathan, et al.. (2021). Cognitive Go/No-Go decision-making criteria in Alzheimer’s disease drug development. Drug Discovery Today. 26(5). 1330–1336. 4 indexed citations

Jutten, Roos J., John Harrison, Silvia Ingala, et al.. (2019). Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. Alzheimer s Research & Therapy. 11(1). 45–45. 23 indexed citations

10.

Kwok, Timothy, Jenny Lee, Ronald C.W., et al.. (2016). A randomized placebo controlled trial of vitamin B12 supplementation to prevent cognitive decline in older diabetic people with borderline low serum vitamin B12. Clinical Nutrition. 36(6). 1509–1515. 49 indexed citations

11.

Mortamais, Marion, Jessica A. Ash, John Harrison, et al.. (2016). Detecting cognitive changes in preclinical Alzheimer's disease: A review of its feasibility. Alzheimer s & Dementia. 13(4). 468–492. 145 indexed citations

12.

Laczó, Jan, Ross Andel, Zuzana Nedelská, et al.. (2016). Exploring the contribution of spatial navigation to cognitive functioning in older adults. Neurobiology of Aging. 51. 67–70. 40 indexed citations

13.

Ritchie, Karen, Michael T. Ropacki, Bruce Albala, et al.. (2016). Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project. Alzheimer s & Dementia. 13(2). 186–195. 69 indexed citations

14.

Harrison, John, et al.. (2016). Assessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome. Journal of Autism and Developmental Disorders. 46(4). 1455–1463. 6 indexed citations

15.

Scheltens, Philip, Jos W. R. Twisk, Rafael Blesa, et al.. (2012). Souvenaid (R) Improves Memory in Drug-Naive Patients with Mild Alzheimer's Disease: Results from a Randomized, Controlled, Double-Blind Study (Souvenir II). Pure Amsterdam UMC. 3 indexed citations

16.

Harrison, John. (2011). Local enterprise partnerships. Figshare. 2 indexed citations

17.

Faux, Noel G., Craig Ritchie, Adam P. Gunn, et al.. (2010). PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. Journal of Alzheimer s Disease. 20(2). 509–516. 321 indexed citations

18.

Xie, Gang, John Harrison, Steven J. Clapcote, et al.. (2010). A New Kv1.2 Channelopathy Underlying Cerebellar Ataxia. Journal of Biological Chemistry. 285(42). 32160–32173. 73 indexed citations

19.

Snyder, Peter J., Rebecca Kaufman, John Harrison, & Paul Maruff. (2010). Charles Darwin's Emotional Expression “Experiment” and His Contribution to Modern Neuropharmacology. Journal of the History of the Neurosciences. 19(2). 158–170. 10 indexed citations

20.

Harrison, John, Sonia L. Minassian, Lisa Jenkins, et al.. (2007). A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials. Archives of Neurology. 64(9). 1323–1323. 156 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact